Recently Updated Guidelines
Guidelines for Treatment of Cancer by Type
-
Bladder Cancer Version 5.2024
-
Breast Cancer Version 6.2024
-
Chronic Myeloid Leukemia Version 2.2025
-
Head and Neck Cancers Version 5.2024
-
Kaposi Sarcoma Version 1.2025
-
Mesothelioma: Peritoneal Version 1.2025
-
Mesothelioma: Pleural Version 1.2025
-
Myelodysplastic Syndromes Version 1.2025
-
Pediatric Central Nervous System Cancers Version 1.2025
-
Penile Cancer Version 1.2025
-
Primary Cutaneous Lymphomas Version 1.2025
-
Small Cell Lung Cancer Version 3.2025
-
Soft Tissue Sarcoma Version 4.2024
-
T-Cell Lymphomas Version 1.2025
-
Testicular Cancer Version 2.2024
-
Thymomas and Thymic Carcinomas Version 1.2025
-
Wilms Tumor (Nephroblastoma) Version 2.2024
-
NCCN Guidelines with Evidence Blocks - Bladder Cancer Version 5.2024
-
NCCN Guidelines with Evidence Blocks - Breast Cancer Version 6.2024
-
NCCN Guidelines with Evidence Blocks - Chronic Myeloid Leukemia Version 2.2025
-
NCCN Guidelines with Evidence Blocks - Head and Neck Cancers Version 5.2024
-
NCCN Guidelines with Evidence Blocks - Kaposi Sarcoma Version 1.2025
-
NCCN Guidelines with Evidence Blocks - Pediatric Central Nervous System Cancers Version 1.2025
-
NCCN Guidelines with Evidence Blocks - Penile Cancer Version 1.2025
-
NCCN Guidelines with Evidence Blocks - Primary Cutaneous Lymphomas Version 1.2025
-
NCCN Guidelines with Evidence Blocks - Small Cell Lung Cancer Version 3.2025
-
NCCN Guidelines with Evidence Blocks - Soft Tissue Sarcoma Version 4.2024
-
NCCN Guidelines with Evidence Blocks - T-Cell Lymphomas Version 1.2025
-
NCCN Guidelines with Evidence Blocks - Testicular Cancer Version 2.2024
Guidelines for Detection, Prevention, & Risk Reduction
Guidelines for Supportive Care
-
Cancer-Related Fatigue Version 1.2025
-
Distress Management Version 1.2025
-
Management of Immunotherapy-Related Toxicities Version 2.2024
-
Palliative Care Version 1.2025
-
Smoking Cessation Version 2.2024
Guidelines for Specific Populations
-
Cancer in People with HIV Version 1.2025